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Abstract: We have previously shown that the Wnt canonical pathway (WCP) is constitutively active in
most cases of mantle cell lymphoma (MCL). Here, we aimed to elucidate the mechanisms underlying
this biochemical deregulation. We hypothesized that gene methylation/silencing of WIF1 (Wnt
inhibitory factor-1), a physiologic inhibitor of WCP, contributes to the deregulation of WCP and
promotes cell growth in MCL. In support of this hypothesis, we found that the expression of WIF1
was detectable in none of the 4 MCL cell lines, and in only 2 of 5 tumors (40%) examined. Using
methylation-specific PCR, we found evidence of gene methylation of WIF1 in 4 of 5 cell lines (80%)
and in 24 of 29 (82%) tumors. The addition of the demethylation agent 5-aza-2′-deoxycytidine to mino
and JeKo-1, two WIF1-negative cell lines, restored the expression of WIF1 mRNA in these cells. Gene
transfection of WIF1 into JeKo-1 and mino cells significantly reduced cell growth, and this finding
correlated with substantial downregulations of various proteins in WCP, such as β-catenin and
pGSK-3β. In conclusion, our results support the concept that gene methylation/silencing of WIF1 is
a frequent event in MCL, and this abnormality contributes to the aberrant activation of WCP. These
results have provided further evidence that aberrant Wnt signaling is pathogenetically important in
MCL and it may represent a potential therapeutic target.
Keywords: mantle cell lymphoma; Wnt canonical pathway; Wnt inhibitory factor-1; gene methylation
1. Introduction
Mantle cell lymphoma (MCL) is a type of aggressive B-cell non-Hodgkin lymphoma
that carries a guarded prognosis despite a high rate of initial remission induced by con-
ventional chemotherapy regimens [1,2]. Most of these tumors harbor the characteristic
chromosomal translocation, t(11;14) (q13;q32), which brings the cyclin D1 gene under
the influence of the enhancer of IgH, resulting in aberrant cyclin D1 expression in these
neoplastic B-cells [3]. In view of its normal function, cyclin D1 is believed to drive tu-
morigenesis by promoting cell-cycle progression. Nevertheless, more recent studies have
provided evidence that cyclin D1 may promote tumorigenesis via functions unrelated to its
cell-cycle regulatory functions [4–6]. It is also widely believed that the over-expression of
cyclin D1 alone is not sufficient for lymphomagenesis. For example, cyclin D1 transgenic
mice do not have spontaneous lymphoma formation. For instance, in the animal model
described by Smith et al, MCL-like tumors were induced in Eµ-cyclin D1 transgenic mice
only after injection with pristane, a tumor promoter [7]. Thus, oncogenic events additional
to the aberrant over-expression of cyclin D1 are likely to be important for the development
of MCL.
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Constitutive activation of the Wnt canonical pathway (WCP) has been shown to pro-
mote tumorigenesis in many types of cancer [8–13]. Details of WCP have been reviewed
elsewhere [14–16]. Normally, activation of WCP is initiated by the binding of various
Wnt ligands to their respective cell-surface receptors that are made up of the frizzled
family members and the low-density lipoprotein receptor-related protein (LRP)-5 or LRP-6.
This event leads to the inactivation of the destruction complex consisting of glycogen
synthase kinase (GSK)-3β, axin, and adenomatous polyposis coli (APC), involving the
phosphorylation of GSK-3β and the subsequent nuclear accumulation of β-catenin. In com-
plex with the T-cell factor (TCF)/lymphocyte-enhancing factor (LEF) family of transcription
factors, β-catenin modulates the transcription of a host of important genes encoding Myc,
cyclin D1, and various Wnt agonists. In many types of cancer, WCP is constitutively active,
and this aberrancy has been shown to promote cell proliferation and survival. Correlating
with this, the activation status of WCP has been shown to significantly correlate with a
worse clinical outcome. For example, our group has previously demonstrated that GSK-
3β phosphorylation and inactivation, which was found in most cases of MCL examined,
significantly correlates with a short survival [17].
The mechanisms underlying the constitutive activation of WCP in MCL have not been
extensively studied. We hypothesized that the expression of naturally occurring WCP
inhibitors might be defective in these neoplastic B-cells. In this study, we evaluated the
expression status of one of these inhibitors, Wnt inhibitory factor-1 (WIF1), which is a
secreted protein that normally binds to Wnt ligands and prevents them from activating
the WCP.
2. Results
2.1. Expression of WIF1 in MCL Cell Lines and Patient Tumor Samples
To examine the expression of WIF1 in MCL, we performed RT-PCR and Western blot
studies. As shown in Figure 1A,B, WIF1 mRNA and WIF1 protein were not detectable in
all 4 MCL cell lines examined, including SP53, JeKo-1, mino, and Rec1. Using RT-PCR to
detect WIF1 mRNA in 5 cases of MCL tumors from previously untreated patients, WIF1
expression was detected in only 2 out of the 5 (40%) samples (Figure 1C).
2.2. WIF1 Is Hypermethylated in Most MCL Cell Lines and Tumors
We speculated that WIF1 is not expressed in most MCL cell lines and patient samples
due to gene methylation and silencing. Thus, we employed methylation-specific PCR.
As shown in Figure 2A, 4 out of 5 (80%) MCL cell lines showed amplification with the
methylation-specific primer set, with Rec1 being the only cell line showing no detectable
evidence of gene methylation. Using the same primer set and PCR condition, we examined
the methylation status of the WIF1 promoter in 29 tumor samples from previously untreated
MCL patients. Twenty-four out of the 29 (83%) patient samples showed evidence of WIF1
gene methylation (illustrated in Figure 2B).
We have previously published that the expression of phosphorylated/inactivated
GSK-3β (pGSK-3β) is detectable in approximately two-thirds of MCL tumors [17]. In this
same study, the expression of pGSK-3β was found to significantly correlate with the nuclear
expression of β-catenin. Thus, we asked if the methylation status of WIF1 correlates with
the expression of pGSK-3β. As shown in Table 1, the methylation status of WIF1 was
in alignment with the expression of pGSK-3β in 21 of 29 (72.4%) cases. Specifically, the
presence of WIF1 methylation correlates with the expression of pGSK-3β, or vice versa.
The overall correlation between these two parameters is statistically significant (p = 0.038).
A handful of ‘outliers’ were identified. Six (21%) cases had WIF1 methylation that was
coupled with a low level of pGSK-3β. Only 2 (6.9%) cases showed a high expression of
pGSK-3β in the absence of WIF1 methylation.
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Figure 2. High methylation status of the WIF1 promoter region in MCL cell lines and patients. (A) 
Methylation-specific PCR of the WIF1 promoter region was performed on 5 MCL cell lines. With 
the exception of REC1, signals from the methylation-specific PCR were readily detectable. (B) 
Methylation-specific PCR of WIF1 promoter region performed on 4 MCL patient samples. M indi-
cates primer specific for methylated site, U indicates primer specific for unmethylated site. Neg 
indicates no DNA negative control. 
Table 1. A significant correlation between the high expression of pGSK-3β and WIF1 methylation 
in 29 cases of mantle cell lymphoma. 
Methylation Status Low pGSK-3β High pGSK-3β p Value 
WIF1 methylation detected 6 15 
0.038 WIF1 methylation NOT de-
tected. 6 2 
2.3. WIF1 Expression is Restored by Treatment with Demethylation Agent 5-aza 
We then determined whether gene methylation is directly responsible for the si-
lencing of WIF1 in MCL cells. Thus, we treated JeKo-1 and Mino—both of which showed 
evidence of WIF1 gene methylation—with 5-aza, a commonly used demethylation agent. 
As shown in Figure 3, WIF1 mRNA expression in both JeKo-1 and Mino cells signifi-
cantly increased after the 5-aza treatment. 
 
Figure 3. The expression of WIF1 mRNA was dramatically increased in (A) JeKo-1 and (B) Mino 
cells after the treatment with the demethylating agent, 5-aza. ** p value < 0.001. 
2.4. WIF1 Decreases β-Catenin and pGSK-3β Expression in MCL Cell Lines 
In vitro experiments were conducted using two MCL cell lines (JeKo-1 and Mino). As 
shown in Figure 4, we found that gene transfection of WIF1 resulted in more than 45% 
reduction in the protein levels of β-catenin and pGSK-3β. These findings suggest that the 
Figure 2. High methylation status of the WIF1 promoter region in MCL cell lines and patients.
(A) Methylation-specific PCR of the WIF1 promoter region was performed on 5 MCL cell lines.
With the exception of REC1, signals from the methylation-specific PCR ere readily detectable.
(B) Methylation-specific PCR of WIF1 promoter region performed on 4 MCL patient samples. M indi-
cates primer specific for methylated site, U indicates primer specific for unmethylated site. Neg indi-
cates no DNA negative control.
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Table 1. A significant correlation between the high expression of pGSK-3β and WIF1 methylation in
29 cases of mantle cell lymphoma.
Methylation Status Low pGSK-3β High pGSK-3β p Value
WIF1 methylation detected 6 15
0.038
WIF1 methylation NOT detected. 6 2
2.3. WIF1 Expression Is Restored by Treatment with Demethylation Agent 5-aza
We then determined whether gene methylation is directly responsible for the silencing
of WIF1 in MCL cells. Thus, we treated JeKo-1 and mino—both of which showed evidence
of WIF1 gene methylation—with 5-aza, a commonly used demethylation agent. As shown
in Figure 3, WIF1 mRNA expression in both JeKo-1 and mino cells significantly increased
after the 5-aza treatment.
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Figure 3. The expression of WIF1 mRNA was dramatically increased in (A) JeKo-1 and (B) mino cells
after the treatment with the demethylating agent, 5-aza. ** p value < 0.001.
2.4. WIF1 Decreases β-Catenin and pGSK-3β Expression in MCL Cell Lines
In vitro experi ents ere con cte sing two MCL cell lines (JeKo-1 and mino).
As shown in Figure 4, we found that gene transfection f I 1 res lte i ore than 45%
reduction in the protein levels of β-catenin and pGSK-3β. These findings sug est that the
loss of WIF1 expression is indeed an important contributor to the constitutive activation
in MCL.
2.5. WIF1 Inhibits MCL Cell Growth and Sensitizes Them to Cytarabine (Ara-C)
We then assessed if the restoration of WIF1 by gene transfection can induce any
biological changes. As shown in Figure 5A, transfection of WIF1 significantly reduced
the cell growth by 20–30% in both JeKo-1 and mino cells. Triplicate experiments were
performed, and results from a representative run are illustrated. Furthermore, WIF1-
transfected JeKo-1 cells sensitized these cells to the chemotherapeutic drug cytarabine
(Ara-C). Ara-C was added to WIF1-transfected JeKo-1 cells 24 h after the gene transfection,
the number of viable cells was quantified using MTS assay 48 h after the addition of
Ara-C. As shown in Figure 5B, restoration of WIF1 significantly sensitized JeKo-1 cells to
Ara-C-induced inhibition on cell growth.
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3. Discussion
Despite the recent advances in therapeutics, the overall prognosis of MCL remains
guarded and disease relapses are relatively frequent [1,2]. Identification of new therapeutic
targets is somewhat limited by incomplete understanding of the biology of this disease.
Another confounding factor is that MCL is increasingly recognized to be heterogeneous,
both biologically and clinically. Defects in WCP were initially reported by our group [18],
in which we employed immunohistochemistry and identified 33 (52%) of 64 MCL tumors
showing constitutive WCP activation, as evidenced by the nuclear localization of β-catenin
and the expression of the p-GSK3β. In a follow-up study, we found that a high expression of
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p-GSK3β, which made up 67.5% of our MCL cohort (n = 83) correlated with a significantly
shorter overall survival [17]. In a subsequent study using gene profiling comparing MCL
cells from patient’s peripheral blood samples with normal tonsillar B-cells, a research group
identified additional evidence that WCP is deregulated in MCL [19]. Taken together, it
appears that deregulations of WCP exist in a subset of MCL tumors and these defects carry
prognostic implications in this disease.
DNA methylation is the one of key biological processes under the realm of epigenetic
gene regulation. In humans, it occurs on the cytosine residue in the CpG-rich region
that is commonly found in the promoter region of many genes. Hypermethylation of
various tumor suppressor genes is known to be an important mechanism to contribute
to the pathogenesis of many types of cancer [20–23]. Accordingly, various studies have
shown that restoration of the expression of tumor suppressors, using gene transfection
or pharmacologic agents (e.g. 5-AZA), has been shown to induce effective apoptosis
and cell growth arrest in cancer cells. Demethylation agents have also been clinically
used as anti-cancer agents [24–26]. Regarding WIF1, our literature search has identified
relatively few studies detecting WIF1 methylation in various tumors [27–30]. This defect
has been reported to carry prognostic significance in several types of solid tumors, such
as colorectal carcinoma [31] and endometrial carcinoma [32]. While most of these studies
focused on the detection of WIF1 methylation in their cohorts of clinical samples and
its prognostic value, the biological significance of this defect was not examined in detail.
To our knowledge, studies of WIF1 methylation in hematologic malignancies are found
only in 5 studies [10,13,33–35], to be further discussed below.
In this study, we have shown that WIF1 methylation is a highly frequent event in
MCL, amounting to 82% of the tumors included in our study cohort. Furthermore, we have
provided direct evidence that this defect is biologically significant, since the restoration
of WIF1 expression can downregulate the activation status of WCP, suppress cell growth
and sensitize MCL cells to Ara-C-induced growth inhibition. These findings are in par-
allel with those described in the previous studies in which the biological significance of
WIF1 methylation in cancers was examined. Nonetheless, most of these studies of WIF1
methylation in hematological malignancies did not examine the biological significance of
this defect. For instance, Chim et al surveyed a cohort of chronic lymphocytic leukemias
and found that WIF1 is infrequently methylated in these neoplasms [36]. In another article
published by Griffiths et al, WIF1 hypermethylation was detected in 32% of acute myeloid
leukemia samples [13]. One of the 5 studies of WIF1 in hematologic malignancies is related
to MCL [33]. In this study, it was demonstrated that WIF1 was not detectable in all 4 MCL
cell lines examined, although MCL tumors were not included. Functional studies, which
involved WIF1 gene transfection, were performed only in a diffuse large B-cell lymphoma
cell line (i.e. Pfeiffer). Taken together, results from this current study have shown for the
first time that WIF gene methylation/silencing is highly frequent in MCL tumors and
we have provided direct evidence that WIF1 gene methylation is biologically significant
in MCL.
Due to the relatively high frequency of WIF1 methylation in our MCL cohort, a
determination of the prognostic value of this biomarker is rather difficult. Nonetheless,
we found a statistical correlation between WIF1 methylation and the high expression of
pGSK-3β, and this finding suggests that WIF1 methylation may also have prognostic value.
Regarding the ‘outliers’, most of these cases showed evidence of WIF1 methylation that
was coupled with a low level of pGSK-3β. One explanation for this apparent mismatch
may be related to a failure of the immunohistochemical detection of pGSK-3β, possibly due
to suboptimal antigen preservation. Another possible explanation is related to the existence
of additional defects (e.g. mutations) in the downstream pathway of WCP, leading to a
failure of phosphorylation/inactivation of GSK-3β. Relevant to the second explanation,
it has been reported that restoration of WIF1 expression in colorectal cancer cell lines can
induce significant apoptosis in these cells, despite the fact that they are known to carry
WCP downstream mutations [37]. These observations suggest that WIF1 may exert tumor
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suppressor functions independent of the downstream WCP pathway. In other words,
restoration of WIF1 may be therapeutically useful even in these ‘outlier’ cases, since the
WIF1 can mediate tumor suppressor effects via other mechanisms.
In conclusion, we have demonstrated that WIF1 is frequently silenced epigenetically in
MCL cell lines and tumors. We have provided direct evidence that this defect is biologically
significant in MCL. Our finding of a significant correlation between the expression of
pGSK-3β and WIF1 gene methylation has provided some degree of validation that this
biochemical defect is likely biologically significant in MCL tumors as well. Further studies
may be focused on testing if restoration of WIF1 is a feasible therapeutic approach in
treating MCL.
4. Materials and Methods
4.1. Cell Lines and Tumor Samples
Five previously described MCL cell lines, JeKo-1, mino, SP53, Granta, and Rec1, were
used in this study. Briefly, the five cell lines carry a mature B-cell immunophenotype,
they are negative for the Epstein-Barr virus nuclear antigen, positive for cyclin D1 over-
expression, and the t(11;14)(q13;q32) cytogenetic abnormality. Cell lines were grown in
RPMI 1640 supplemented with 10% fetal bovine serum and glutamine under a 5% CO2
atmosphere. All MCL tumors were diagnosed at the Cross Cancer Institute (Edmonton,
Alberta, Canada) between 1994 and 2007, and the diagnostic criteria were based on those
described in the World Health Organization Classification Scheme [38]. All cases were
confirmed to over-express cyclin D1 by immunohistochemistry. The use of these tissues
was approved by our institutional ethics committee (approval number Pro00062737; expiry
date 25 November 2021).
4.2. Reverse Transcription-PCR
Total RNA from MCL cell lines and MCL patient samples was isolated using TRIzol
(Invitrogen, Carlsbad, CA, USA) in accordance with the manufacturer’s suggested protocol.
Briefly, cDNA synthesis was carried out for 30 min at 42 ◦C using SuperScript Reverse
Transcriptase II (Invitrogen). The PCR was performed for 30 cycles in a thermal cycler
(Applied Biosystems, Streetville, Ontario, Canada), with each consisting of denaturation
(94 ◦C for 1 min), primer annealing (58 ◦C for 1 min), and DNA extension (72 ◦C for 1.5 min
for 30 cycles). Amplified products were electrophoresed in 2% agarose gel containing
ethidium bromide and visualized using an Alpha Imager 3400 (Alpha Innotech, San
Leandro, CA, USA). Primers for reverse transcription PCR were obtained from Invitrogen
(Alameda, CA). A total of 500 ng RNA was used in each reaction. Primer sequences were
as follows: forward primer 5′ CCG AAA TGG AGG CTT TTG TA 3′, reverse primer 5′
GTG TCT TCC ATG CCA ACC TT 3′ (product size 451 bp). Glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) was used as an internal control.
4.3. Methylation Specific PCR (MSP)
DNA was extracted from paraffin-embedded MCL tumor tissue and MCL cell lines
using the Qiagen DNeasy Tissue Kit according to the manufacturer’s protocol (Qiagen,
Mississauga, Ontario, Canada). Bisulfite-treated genomic DNA was amplified using either a
methylation-specific or an unmethylation-specific primer set. HotStarTaq DNA polymerase
(Qiagen) was used in the experiments. Sequences of the methylation-specific primers were
5′-GGGCGTTTTATTGGGCGTAT-3′ (forward) and 5′-AAACCAACAATCAACGAAC-3′
(reverse). Sequences of the unmethylation-specific primers were 5′-GGGTGTTTTATTGG
GTGTAT-3′ (forward) and 5′-AAACCAACAATCAACAAAAC-3′ (reverse) corresponding to
the WIF1 promoter region sequences −488 to −468 and −310 to −290, respectively [39,40].
4.4. Treatment with 5-aza-2’-deoxycytidine
5-Aza-2’-deoxycytidine (Sigma-Aldrich, Toronto, Ontario, Canada) was dissolved in
50% acetic acid and diluted to 10 µg/µL and aliquots were stored at −20 ◦C. Cells were
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seeded at a density of 0.5 × 106 per mL in 6-well plates. 5-Aza was diluted in fresh RPMI
medium and added to the culture medium to final concentrations of 5 and 10 µM every
24 h for 3 days. Sterilized 50% acetic acid at a concentration approximately equal to that
used for 5-aza-treated cultures was added to negative control cultures every 24 h for 3 days.
4.5. Western Blot Analysis and Antibodies
Western blot analysis was performed using standard techniques. Briefly, the cells were
washed with phosphate-buffered saline (PBS), and cellular proteins were precipitated using
RIPA buffer containing 150 mM NaCl, 1%NP40, 0.5% deoxycholic acid, 0.1% SDS, 50 mM
Tris pH8 which was supplemented with 40.0 µg/mL leupeptin, 1 µM pepstatin, 1 mM
4-(2-aminoethyl)-benzenesulfonyl fluoride (AEBSF) and 0.1 mM phenylmethylsulfonyl-
fluoride (PMSF). The protein concentration of the samples was determined using BCA
Protein Assay Kit (Pierce, Thermo Fisher Scientific Inc, Rockford, IL, USA). The supernatant
was removed and 50 µg of protein was run on an 8%-12% SDS polyacrylamide gel. After
the proteins were transferred to nitrocellulose membranes, the membranes were blocked
with 5% milk in tris-buffered saline (TBS) buffer (20 mM Tris-HCl, pH 7.6, 150 mM NaCl),
and then incubated with primary antibodies overnight at 4 ◦C temperature followed
by 1 h incubation with horseradish peroxidase-conjugated secondary antibody (Jackson
Immunoresearch Laboratories, Inc., West Grove, PA, USA). The membranes were washed
in PBS with 0.1% Tween-20 for 30 min between steps. Proteins were detected using the
Enhanced Chemiluminescence Detection Kit (Amersham Life Sciences, Arlington Heights,
IL, USA). Antibodies used were: anti-WIF1 (1:500) and anti-pGSK3β (1:1000, Ser9) (Cell
Signaling, Danvers, MA, USA), anti- β-catenin (amino acid residue 571–581, 1:500, BD
Transduction laboratories, Lexington, KY, USA), and anti-actin (1:3000, Sigma-Aldrich,
St Louis, MO, USA).
4.6. Lentiviral Gene Transfection
WIF1 overexpression was assessed using two different methods. (1) The WIF1 expres-
sion vector pcDNA3.1 vector was a generous gift from Professor Qian Tao, Cancer Center,
Chinese University of Hong Kong. Transient transfections of MCL cells (10 × 106 cells)
were performed using the Electro square electroporator (BTX ECM 800, Holliston, MA,
USA) (225 V, 8.5 msec, 03 pulse) using 1 µg of WIF1 or empty vector per million MCL cells.
Cells were harvested at 48 h after transfection. The efficiency of target gene overexpression
was assessed using Western blot. (2) Lentiviral particles were generated by transfecting the
293T packaging cell line (Clontech Laboratories, Inc., Fremont, CA, USA) with the WIF1
lentiviral vector (pLenti-GIII-CMV-Puro) (Applied Biological Materials Inc., Richmond,
BC, Canada) or its control (pLVX-Puro lentiviral vector) (Clontech Laboratories, Inc., Fre-
mont, CA, USA), according to the manufacturer’s suggestion. CMV sequencing primer
5′-CGCAAATGGGCGGTAGGCGTG-3′ in which WIF1 sequenced and verified. JeKo-1
and mino cells were infected with lentiviral particles at 24 and 48 h. Forty-eight hours after
the second infection, cells were washed with phosphate-buffered saline (PBS) and lysed
using the previous Western blot protocol.
4.7. MTS Assay and Cell Viability
MCL cell lines in RPMI 1640 were seeded 48 h post-transfection in a 96-well plate and
the assay was conducted following the manufacturer’s instructions (Promega, Nepean,
ON, Canada). The measurements were obtained at a wavelength of 450 nM using a Biorad
Microplate Reader. The absorbance values were normalized to the untreated cells using
the microplate Manager 5.2.1 software (Biorad, Hercules, CA, USA). All experiments were
performed in triplicate. Cell viability was determined using the trypan blue exclusion test
and results expressed as the total number of viable cells.
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4.8. Statistical Analysis
Data are expressed as mean +/− standard derivation. Statistical significance was
tested using Student’s t-test and statistical significance was achieved when the p value
was <0.05.
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